SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as investors prepare for a critical FDA advisory committee meeting on July 29 regarding deramiocel, a treatment for Duchenne muscular dystrophy. The community is focused on the potential for a dual-label approval for both skeletal and cardiac function, while actively debating the impact of recent briefing documentation and high short interest on the stock's near-term volatility.

D-Wave Quantum, Inc. engages in the development and delivery of quantum computing systems, software, and services. It provides customers with access to the company’s quantum computing systems via the cloud in the form of quantum computing as a service. It offers professional services such as customer assistance in identifying and implementing quantum-computing applications. The company was founded on January 25, 2022 and is headquartered in Palo Alto, CA.

D-Wave Quantum Inc

D-Wave Quantum is trending as investors react to the company's securing of a significant National Science Foundation grant and its inclusion as a Leader in a major industry assessment. The community is actively debating the company's valuation and long-term potential, with many focusing on whether recent government-backed quantum initiatives will successfully translate into sustainable commercial growth.

Rigetti Computing, Inc. provides full-stack quantum computing services. It serves global enterprise, government, and research clients through its Rigetti Quantum Cloud Services platform. The company was founded by Chad Rigetti in 2013 and is headquartered in Berkeley, CA.

Rigetti Computing Inc

Rigetti Computing is trending as investors react to new executive orders designed to accelerate national quantum technology leadership and secure data migration. While some community members view this as a potential long-term catalyst for growth, others remain cautious, actively debating the stock's high cash burn, recent insider selling, and concerns that these government-linked announcements may lead to volatility rather than sustained upside.

Critical Metals Corp. engages in the mining, exploration, and development of lithium metals. It owns Wolfsberg Project and Tanbreez Project. The company was founded on October 24, 2022 and is headquartered in British Virgin Islands.

Critical Metals Corp.

Critical Metals Corp. is trending as investors weigh its potential as a key player in Western rare earth supply chains against volatility in the critical minerals sector and ongoing discussions regarding its Tanbreez project's development timeline. Community discourse is highly polarized, with intense debate centered on management transparency, the impact of recent dilution, and speculation surrounding upcoming tender opportunities for major rare earth deposits.

Omeros Corp. operates as a biopharmaceutical company, which engages in the research, discovery, development, and commercialization of small-molecule and protein therapeutics targeting immunologic diseases. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros Corp is trending as investors react to a negative CHMP opinion on YARTEMLEA in Europe, triggering significant volatility despite ongoing U.S. commercial efforts. The community is actively debating the impact of the EMA setback versus the potential for a successful appeal and upcoming domestic catalysts like J-code implementation.

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. Its lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner on May 3, 2017 and is headquartered in Dallas, TX.

Forte Biosciences Inc

Forte Biosciences is surging after announcing a 53 million dollar private placement, which has triggered intense community speculation regarding potential institutional backing and a significant short squeeze. Traders are actively debating the stock's momentum versus the high risk of future dilution, as the company works to fund the development of its autoimmune pipeline.

Litecoin is a decentralized, peer-to-peer digital currency designed to enable instant, near-zero cost payments to individuals and merchants worldwide. As an open-source global payment network that functions independently of central banks or intermediaries, its main value proposition lies in providing a scarce digital asset with a fixed maximum supply of 84 million tokens.  The network operates using a Proof of Work mechanism where computers solve complex puzzles to confirm transactions and secure the blockchain. It is distinguished by a block generation time of 2.5 minutes, which allows for faster transaction confirmations and a higher total throughput than earlier protocols. Key technical features include the Scrypt hashing algorithm, which promotes wider network participation, and MimbleWimble Extension Blocks, which improve user privacy by allowing transaction details to be hidden.  The LTC token is used for settling global payments, executing microtransactions through smaller units called litoshis, and diversifying digital portfolios with a highly liquid asset. New tokens are issued to miners as rewards for verifying blocks, though these rewards undergo a halving event approximately every four years to strictly control inflation. This process ensures the ledger maintains immutability, meaning records cannot be changed once they are saved to the global network.  Created by former Google engineer Charlie Lee, the project is supported by the Litecoin Foundation, a non-profit organization dedicated to ecosystem adoption. Unlike many venture-backed projects, it is maintained by a decentralized community of independent developers and a global network of miners. The project has seen recent institutional adoption, with entities like Lite Strategy and Luxxfolio Holdings adding significant amounts of LTC to their corporate treasuries as of late 2025.

Litecoin

Litecoin is experiencing heightened activity as traders debate whether it is forming a major macro bottom or faces further downside, with the community closely tracking its interaction with key price levels and institutional custody developments. Speculation remains intense regarding whether current technical structures and market indicators signal an imminent breakout or continued consolidation, fueled by ongoing debates over its long-term utility.

Legend Biotech Corp. is a clinical-stage biopharmaceutical company, which engages in the discovery, development, manufacturing, and commercialization of novel therapies for oncology and other indications. The firm develops advanced cell therapies across a diverse array of technology platforms, including autologous and allogeneic chimeric antigen receptor T-cell, gamma-delta T cell and natural killer cell-based immunotherapy. It operates through the following geographical segments: United States of America, China, and Other. The company was founded in 2014 and is headquartered in Somerset, NJ.

Legend Biotech Corp - ADR

Legend Biotech

Legend Biotech is facing significant downward pressure following leadership changes and investor concerns over competitive threats from new therapies in the multiple myeloma space. While community sentiment remains divided, many investors are focused on the company's strong sales growth and potential for a strategic acquisition to unlock value.

ProShares Trust II - ProShares UltraShort Bloomberg Crude Oil -2x Shares

ProShares UltraShort Bloomberg Crude Oil

ProShares UltraShort Bloomberg Crude Oil (SCO) is facing significant downward pressure as supply disruptions in the Strait of Hormuz keep oil prices elevated, causing the ETF to struggle with volatility decay and divergence from its daily performance targets. The community is actively debating whether to treat this as a tactical swing trade on potential de-escalation news or to exit positions due to the fund's poor long-term performance and pending reverse split.

Anthropic

Anthropic is currently in the spotlight due to high-stakes regulatory scrutiny regarding export controls and national security concerns, which have impacted access to its latest models. Amid this, the community is actively debating the company's aggressive infrastructure partnerships, valuation, and the broader race toward a highly anticipated IPO.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Does Cobenfy Have the Potential to Become a Top Drug for BMY?

BMY's Cobenfy gains traction with $155M in 2025 sales, outpacing peers and showing strong uptake as Bristol Myers eyes new indications and growth.

Why Did RVPH Stock Crash 40% In Pre-Market Today?

Equity

The company priced its $10 million offering at a 20% discount from Wednesday’s close.

Investors Purchase Large Volume of Call Options on Reviva Pharmaceuticals (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) was the recipient of unusually large options trading activity on Wednesday. Stock traders acquired 25,745 call options on the...

Why Did RVPH Stock Crash 50% Today?

The company announced that the FDA called for an additional Phase 3 trial of its schizophrenia treatment drug.

Reviva Pharmaceuticals (NASDAQ:RVPH) Earns "Buy" Rating from D. Boral Capital

D. Boral Capital reaffirmed a "buy" rating and issued a $2.00 target price on shares of Reviva Pharmaceuticals in a report on Tuesday...

Reviva Pharmaceuticals Sees Unusually High Options Volume (NASDAQ:RVPH)

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) was the recipient of unusually large options trading activity on Tuesday. Stock traders acquired 27,891 call options on the...

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) Given Average Rating of "Moderate Buy" by Brokerages

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Get Free Report) has earned a consensus rating of "Moderate Buy" from the nine brokerages that are currently covering the company, MarketBeat.com...

Brokers Offer Predictions for RVPH FY2025 Earnings

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH - Free Report) - Analysts at Chardan Capital issued their FY2025 earnings per share estimates for Reviva Pharmaceuticals in a research note issued...

Bristol Myers' Cobenfy, the first new schizophrenia treatment in decades, shows early sales momentum and strong pipeline expansion potential.

10 Stocks Retailers Are Most Bullish/Bearish About On Tuesday

Earnings largely impacted sentiment toward stocks that made it to the most bullish and bearish lists on Stocktwits Tuesday.


Reviva Pharmaceuticals Holdings, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutics for the central nervous system, respiratory, and metabolic diseases. It uses chemical genomics driven technology platform and proprietary chemistry to develop new medicines. It focuses on the RP5063 (Brilaroxazine) and RP1208 pipelines. The company was founded by Laxminarayan Bhat on December 11, 2020 and is headquartered in Cupertino, CA.

Reviva Pharmaceuticals Holdings Inc.

Bullish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Earnings

Fundamentals

Info

RVPHReviva Pharmaceuticals Holdings Inc.

Latest RVPH News